Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Next Previous
Trial Profile

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemnifosbuvir/Ruzasvir (Primary) ; Sofosbuvir/velpatasvir
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms C-FORWARD
  • Sponsors Atea Pharmaceuticals

Most Recent Events

  • 22 Dec 2025 According to an Atea Pharmaceuticals media release, company continues to enroll treatment-naive patients in the C-FORWARD trial, which is evaluating the same fixed-dose combination (FDC) regimen in approximately 880 patients across roughly 120 clinical trial sites in up to 17 countries outside North America.
  • 12 Nov 2025 According to Atea Pharmaceuticals media release, company expects patient enrollment in C-FORWARD to be completed mid-2026 with topline results available around the end of 2026.
  • 25 Jun 2025 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top